世界の血友病治療市場

RNCOSが発行した調査報告書(DATA7100507)
◆英語タイトル:Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction Therapy) Outlook 2022
◆商品コード:DATA7100507
◆発行会社(リサーチ会社):RNCOS
◆発行日:2017年5月16日
◆ページ数:95
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Multi UserUSD2,700 ⇒換算¥305,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged bleeding due to the lack of factors required for the clotting of blood. According to World Federation of Hemophilia, about one in 10,000 people are born with this disease. Various types of drugs are injected into the veins of patient in order to replace the clotting factors, which are missing or low in number.
As per RNCOS report “Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction Therapy) Outlook 2022”, the global hemophilia therapeutics market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global hemophilia therapeutics market. The report provides insight about the major drivers, such as increasing awareness about hemophilia and its treatment options, grants and tax credits, for the global hemophilia therapeutics market. Furthermore, few challenges, such as manufacturing difficulties and low switching rate between hemophilia medicines, which are hindering the growth of the global hemophilia therapeutics market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global hemophilia therapeutics market.

The global hemophilia therapeutics market has been segmented on the basis of type of hemophilia, i.e. Hemophilia A, Hemophilia B, and Others. Hemophilia A occupies the largest share in the global hemophilia therapeutics market, owing to the highest prevalence of this type of hemophilia. Moreover, strong pipeline of drugs for Hemophilia A is also helping its market to grow all across the globe.

Furthermore, the global hemophilia therapeutics market has also been segmented on the basis of type of treatment. According to the report, the treatment for hemophilia can either be an on-demand treatment or a prophylaxis treatment. Currently, on-demand treatment dominates the global hemophilia therapeutics market, as patients usually go for treatment only when bleeding episodes occur. However, prophylaxis is forecasted to be the fastest growing segment owing to the requirement of better management of bleeding episodes.

Similarly, the market has also been segmented on the basis of type of therapy into replacement therapy and immune tolerance induction therapy. Apart from these types of therapies, efforts are also being made by various pharmaceutical and biotech companies to develop gene therapy for the treatment of hemophilia. Gene therapy is an evolving field which focuses on correcting defective genes in order to cure genetic diseases, such as hemophilia. Use of gene therapy for hemophilia treatment is a promising option, as hemophilia is caused due to a single genetic defect. Even a minimal success from this procedure can mean significant improvement in quality of life for patients. Numerous companies, such as BioMarin Pharmaceuticals and uniQure, are carrying out clinical trials for gene therapies for the treatment of hemophilia. Hence, gene therapy presents great opportunities for the growth of global hemophilia therapeutics market in the coming years.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global hemophilia therapeutics market. Moreover, the report also highlights various mergers and acquisitions taking place in the global hemophilia therapeutics industry. The pipeline of hemophilia drugs have also been mentioned in the report.

The last section of the report discusses about the prominent players in global hemophilia therapeutics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hemophilia therapeutics market.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Hemophilia: An Overview
4. Market Dynamics
4.1 Drivers
4.1.1 Development of Inhibitors in Hemophilia Patients
4.1.2 Rising Healthcare Expenditure
4.1.3 Increasing Awareness
4.1.4 Rising Life Expectancy
4.1.5 Grants and Tax Credits
4.1.6 Shorter Development Timeline and Orphan Drug Exclusivity (ODE)
4.2 Challenges
4.2.1 Manufacturing Difficulties
4.2.2 Low Switching Rate
4.3 Opportunities
4.3.1 Incessant Launch of New Generation of Recombinant Factor Products
4.3.2 Growing Geriatric Population
5. Global Hemophilia Therapeutics Market Outlook 2022
6. Major Products in Hemophilia Therapeutics Market
6.1 Advate
6.2 NovoSeven/NovoSeven RT
6.3 Kogenate/Kovaltry
6.4 Feiba
6.5 BeneFix
6.6 ReFacto AF/Xyntha
6.7 Eloctate/Elocta
6.8 Alprolix
6.9 Alphanate
6.10 Rixubis
6.11 NovoEight
6.12 Adynovate/Adynovi
7. Market Segmentation by Type of Hemophilia
7.1 Hemophilia A
7.2 Hemophilia B
7.3 Others
8. Market Segmentation by Type of Treatment
8.1 On-Demand
8.2 Prophylaxis
9. Market Segmentation by Type of Therapy
9.1 Replacement Therapy
9.2 Immune Tolerance Induction Therapy
10. Market Segmentation by Geography
10.1 North America
10.2 Europe
10.3 Asia-Pacific
11. Gene Therapy – Future of Hemophilia Treatment
12. Trends & Developments
13. Mergers & Acquisitions
14. Pipeline Analysis
15. Company Profiles
15.1 Novo Nordisk A/S
15.2 Pfizer Inc.
15.3 F. Hoffmann-La Roche Ltd.
15.4 Bayer AG
15.5 Shire plc
15.6 CSL Limited
15.7 Octapharma AG
15.8 Grifols International SA
15.9 Swedish Orphan Biovitrum AB
15.10 Alnylam Pharmaceuticals, Inc.

List of Figures:

Figure 3-1: Hemophilia Genetic Inheritance
Figure 4-1: Global – Population 60 Years or Above (Billion), 2015, 2030 & 2050
Figure 5-1: Global – Hemophilia Therapeutics Market (Billion US$), 2016 & 2022
Figure 6-1: Global – Sales of Advate (Billion US$), 2015 & 2016
Figure 6-2: Global – Sales of NovoSeven/NovoSeven RT (Billion US$), 2015 & 2016
Figure 6-3: Global – Sales of Kogenate/Kovaltry (Billion US$), 2015 & 2016
Figure 6-4: Global – Sales of Feiba (Billion US$), 2015 & 2016
Figure 6-5: Global – Sales of BeneFix (Billion US$), 2015 & 2016
Figure 6-6: Global – Sales of ReFacto AF/Xyntha (Billion US$), 2015 & 2016
Figure 6-7: Global – Sales of Eloctate/Elocta (Billion US$), 2015 & 2016
Figure 6-8: Global – Sales of Alprolix (Billion US$), 2015 & 2016
Figure 6-9: Global – Sales of Alphanate (Billion US$), 2015 & 2016
Figure 6-10: Global – Sales of Rixubis (Billion US$), 2015 & 2016
Figure 6-11: Global – Sales of NovoEight (Billion US$), 2015 & 2016
Figure 6-12: Global – Sales of Adynovate/Adynovi (Billion US$), 2015 & 2016
Figure 7-1: Global – Hemophilia Therapeutics Market Breakup by Type of Hemophilia (%), 2016
Figure 7-2: Global – Hemophilia A Therapeutics Market (Billion US$), 2016 & 2022
Figure 7-3: Global – Hemophilia B Therapeutics Market (Billion US$), 2016 & 2022
Figure 7-4: Global – Other Hemophilia Therapeutics Market (Billion US$), 2016 & 2022
Figure 8-1: Global – Hemophilia Therapeutics Market Breakup by Type of Treatment (%), 2016
Figure 8-2: Global – On-Demand Hemophilia Therapeutics Market (Billion US$), 2016 & 2022
Figure 8-3: Global – Prophylaxis Hemophilia Therapeutics Market (Billion US$), 2016 & 2022
Figure 9-1: Global – Hemophilia Therapeutics Market Breakup by Type of Therapy (%), 2016
Figure 9-2: Global – Replacement Therapy Market for Hemophilia (Billion US$), 2016 & 2022
Figure 9-3: Global – Immune Tolerance Induction Therapy Market for Hemophilia (Billion US$), 2016 & 2022
Figure 10-1: Global – Hemophilia Therapeutics Market Breakup by Geography (%), 2016
Figure 10-2: North America – Hemophilia Therapeutics Market (Billion US$), 2016 & 2022
Figure 10-3: North America – Population 60 Years or Above (Million), 2015, 2030 & 2050 51
Figure 10-4: Europe – Hemophilia Therapeutics Market (Billion US$), 2016 & 2022
Figure 10-5: Asia-Pacific – Hemophilia Therapeutics Market (Billion US$), 2016 & 2022
Figure 11-1: Gene Therapy Using Adenovirus Vector
Figure 15-1: Novo Nordisk A/S – Breakup of Sales by Business Segment (%), 2016
Figure 15-2: Novo Nordisk A/S – Breakup of Sales by Geography (%), 2016
Figure 15-3: Pfizer Inc. – Breakup of Revenue by Business Segment (%), 2016
Figure 15-4: Pfizer Inc. – Breakup of Revenue by Geography (%), 2016
Figure 15-5: F. Hoffmann-La Roche Ltd. – Breakup of Sales by Business Segment (%), 2016
Figure 15-6: Bayer AG – Breakup of Sales by Business Segment (%), 2016
Figure 15-7: Bayer AG – Breakup of Sales by Geography (%), 2016
Figure 15-8: Shire plc – Breakup of Revenue by Geography (%), 2016
Figure 15-9: CSL Limited – Breakup of Revenue by Business Segment (%), FY 2016
Figure 15-10: CSL Limited – Breakup of Revenue by Geography (%), FY 2016
Figure 15-11: Grifols International SA – Breakup of Revenue by Business Segment (%), 2016
Figure 15-12: Grifols International SA – Breakup of Revenue by Geography (%), 2016
Figure 15-13: Swedish Orphan Biovitrum AB – Breakup of Revenue by Product Category (%), 2016
Figure 15-14: Swedish Orphan Biovitrum AB – Breakup of Revenue by Geography (%), 2016

List of Tables:

Table 13-1: Mergers, Acquisitions & Collaborations in Hemophilia Therapeutics Market (2014-2017)
Table 14-1: Global – Hemophilia Products Pipeline Analysis
Table 15-1: Novo Nordisk A/S – Key Financials (Billion US$), 2014-2016
Table 15-2: Novo Nordisk A/S – Marketed Hemophilia Products
Table 15-3: Novo Nordisk A/S – Hemophilia Products in Pipeline
Table 15-4: Pfizer Inc. – Key Financials (Billion US$), 2014-2016
Table 15-5: Pfizer Inc. – Marketed Hemophilia Products
Table 15-6: Pfizer Inc. – Hemophilia Products in Pipeline
Table 15-7: F. Hoffmann-La Roche Ltd. – Key Financials (Billion US$), 2014-2016
Table 15-8: F. Hoffmann-La Roche Ltd. – Hemophilia Products in Pipeline
Table 15-9: Bayer AG – Key Financials (Billion US$), 2014-2016
Table 15-10: Bayer AG – Marketed Hemophilia Products
Table 15-11: Bayer AG – Hemophilia Products in Pipeline
Table 15-12: Shire plc – Key Financials (Billion US$), 2014-2016
Table 15-13: Shire plc – Marketed Hemophilia Products
Table 15-14: Shire plc – Hemophilia Products in Pipeline
Table 15-15: CSL Limited – Key Financials (Billion US$), FY 2014-FY 2016
Table 15-16: CSL Limited – Marketed Hemophilia Products
Table 15-17: CSL Limited – Hemophilia Products in Pipeline
Table 15-18: Octapharma AG – Key Financials (Billion US$), 2014-2016
Table 15-19: Octapharma AG – Marketed Hemophilia Products
Table 15-20: Octapharma AG – Hemophilia Products in Pipeline
Table 15-21: Grifols International SA – Key Financials (Billion US$), 2014-2016
Table 15-22: Grifols International SA – Marketed Hemophilia Products
Table 15-23: Grifols International SA – Hemophilia Products in Pipeline
Table 15-24: Swedish Orphan Biovitrum AB – Key Financials (Billion US$), 2014-2016
Table 15-25: Swedish Orphan Biovitrum AB – Marketed Hemophilia Products
Table 15-26: Swedish Orphan Biovitrum AB – Hemophilia Products in Pipeline
Table 15-27: Alnylam Pharmaceuticals, Inc. – Hemophilia Products in Pipeline



【レポートのキーワード】

血友病治療

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の血友病治療市場(Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction Therapy) Outlook 2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆